Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Y286779-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $205.90 | |
Y286779-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $842.90 |
Highly potent, selective non-peptide CCK2antagonist
Synonyms | 145084-28-2|YM022|YM-022|YM 022|UNII-772CP7W12N|CHEMBL115121|772CP7W12N|3-(3-methylphenyl)-1-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea|(R)-1-(2-Oxo-1-(2-oxo-2-(o-tolyl)ethyl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4 |
---|---|
Specifications & Purity | Moligand™, ≥99%(HPLC) |
Biochemical and Physiological Mechanisms | Extremely potent and highly selective non-peptide CCK2silent antagonist (Kivalues are 68 pM and 63 nM at CCK2and CCK1receptors respectively). Actsin vivoto potently inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation with |
Storage Temp | Room temperature |
Shipped In | Normal |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of CCK 1 receptor;Antagonist of CCK 2 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-(3-methylphenyl)-3-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
---|---|
INCHI | InChI=1S/C32H28N4O3/c1-21-11-10-15-24(19-21)33-32(39)35-30-31(38)36(20-28(37)25-16-7-6-12-22(25)2)27-18-9-8-17-26(27)29(34-30)23-13-4-3-5-14-23/h3-19,30H,20H2,1-2H3,(H2,33,35,39)/t30-/m0/s1 |
InChi Key | YCXFHPUBGMMWJQ-PMERELPUSA-N |
Canonical SMILES | CC1=CC(=CC=C1)NC(=O)NC2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)CC(=O)C5=CC=CC=C5C |
Isomeric SMILES | CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)CC(=O)C5=CC=CC=C5C |
WGK Germany | 3 |
Alternate CAS | 145084-28-2 |
PubChem CID | 122130 |
MeSH Entry Terms | 1-(2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea;YM 022;YM-022;YM022 |
Molecular Weight | 516.6 |
Enter Lot Number to search for COA:
Solubility | Solvent:DMSO, Max Conc. mg/mL: 51.66, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 5.17, Max Conc. mM: 10 |
---|
Pictogram(s) | GHS06 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed |
Precautionary Statements | P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P316:IF SWALLOWED: Get emergency medical help immediately. |
WGK Germany | 3 |
RIDADR | UN28116.1/PGIII |